© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
October 13, 2022
During a case-based roundtable event, Bhavana Pothuri, MD, discussed the use of PARP inhibitors to treat first-line advanced ovarian cancer.
October 12, 2022
Peter Voorhees, MD, discussed managing adverse events related to belantamab mafadotin in patients with relapsed/refractory multiple myeloma during a live event.
October 11, 2022
During a case-based roundtable event, Ashley Evan Ross, MD, PhD, reviewing therapeutic options for a patient with metastatic hormone-sensitive prostate cancer.
Ellen K. Ritchie, MD, discuss the case of a 68-year-old man with high-risk myelofibrosis during a case-based roundtable event.
October 10, 2022
Mark A. Socinski, MD provides insight on biomarker testing to identify patients with NTRK gene fusion-positive non–small cell lung cancer.
During a case-based roundtable event, Christos Vaklavas, MD moderated a discussion about treatment option for a 48-year-old woman with triple negative breast cancer following adjuvant chemotherapy.
October 08, 2022
During a case-based roundtable event, Thomas Hutson, DO, PharmD, discussed challenges with treating a 59-year-old woman with clear cell renal cell carcinoma.
October 06, 2022
During a case-based roundtable event, Joel W. Neal, MD, PhD of Stanford Cancer Institute and a group of peers discussed using molecular testing to detect an EGFR exon 20 insertion in a patient with lung cancer.
During a case-based rountable event, Jasmine Zain, MD of City of Hope, discussed the case of a 79-year-old patients with relapsed or refractory diffuse large B-cell lymphoma.